(SNDX) Syndax Pharmaceuticals - Overview
Stock: Menin Inhibitor, CSF-1R Antibody, HDAC Inhibitor
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 57.2% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.70 |
| Alpha | 27.30 |
| Character TTM | |
|---|---|
| Beta | 1.040 |
| Beta Downside | 1.117 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.74% |
| CAGR/Max DD | -0.09 |
Description: SNDX Syndax Pharmaceuticals January 18, 2026
Syndax Pharmaceuticals (NASDAQ:SNDX) is a commercial-stage biotech focused on oncology, with its flagship menin inhibitor revumenib (Revuforj) targeting relapsed/refractory acute leukemias, and the CSF-1R antibody axatilimab-csfr (Niktimvo) for chronic graft-versus-host disease.
Beyond the lead programs, Syndax is expanding revumenib into nucleophosmin-1-mutated AML (mNPM1) and combination regimens for KMT2A-rearranged leukemias, while also exploring axatilimab for idiopathic pulmonary fibrosis and metastatic colorectal cancer, and Entinostat (a Class I HDAC inhibitor) under a licensing deal with Eddingpharm.
Key metrics (as of the latest 10-Q): market capitalization ≈ $1.2 B, cash and equivalents $420 M, and a quarterly cash burn of $85 M, giving roughly 5 months of runway without additional financing. The company’s R&D spend has risen 38 % YoY, reflecting the accelerated launch of revumenib and the initiation of multiple combination trials.
Sector drivers that materially affect Syndax include the biotech industry’s elevated valuation multiples (average EV/EBITDA ≈ 30× for late-stage oncology firms) and the FDA’s recent willingness to grant accelerated approvals for targeted leukemia therapies, which could shorten time-to-market for revumenib if pivotal data meet endpoints.
For a deeper, data-rich assessment of Syndax’s risk-adjusted upside, you may find the analyst notes on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -311.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.56 > 0.02 and ΔFCF/TA 4.43 > 1.0 |
| NWC/Revenue: 372.6% < 20% (prev 2149 %; Δ -1777 % < -1%) |
| CFO/TA -0.56 > 3% & CFO -310.9m > Net Income -311.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.6m) vs 12m ago 1.39% < -2% |
| Gross Margin: 91.60% > 18% (prev -1.70%; Δ 9330 % > 0.5%) |
| Asset Turnover: 22.82% > 50% (prev 3.88%; Δ 18.94% > 0%) |
| Interest Coverage Ratio: -10.41 > 6 (EBITDA TTM -294.8m / Interest Expense TTM 23.7m) |
Altman Z'' -10.41
| A: 0.75 (Total Current Assets 529.8m - Total Current Liabilities 114.2m) / Total Assets 551.8m |
| B: -2.61 (Retained Earnings -1.44b / Total Assets 551.8m) |
| C: -0.51 (EBIT TTM -247.0m / Avg Total Assets 488.8m) |
| D: -3.30 (Book Value of Equity -1.44b / Total Liabilities 436.4m) |
| Altman-Z'' Score: -10.41 = D |
Beneish M 1.00
| DSRI: 0.80 (Receivables 25.4m/4.69m, Revenue 111.6m/16.5m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.53 (AQ_t 0.04 / AQ_t-1 0.02) |
| SGI: 6.75 (Revenue 111.6m / 16.5m) |
| TATA: -0.00 (NI -311.6m - CFO -310.9m) / TA 551.8m) |
| Beneish M-Score: 1.25 (Cap -4..+1) = D |
What is the price of SNDX shares?
Over the past week, the price has changed by -1.59%, over one month by -1.78%, over three months by +33.65% and over the past year by +38.86%.
Is SNDX a buy, sell or hold?
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SNDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39.3 | 87.1% |
| Analysts Target Price | 39.3 | 87.1% |
| ValueRay Target Price | 24 | 14% |
SNDX Fundamental Data Overview February 03, 2026
P/B = 15.3003
Revenue TTM = 111.6m USD
EBIT TTM = -247.0m USD
EBITDA TTM = -294.8m USD
Long Term Debt = 331.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 23.3m USD (from shortTermDebt, last quarter)
Debt = 345.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 228.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.66b USD (1.77b + Debt 345.4m - CCE 454.2m)
Interest Coverage Ratio = -10.41 (Ebit TTM -247.0m / Interest Expense TTM 23.7m)
EV/FCF = -5.33x (Enterprise Value 1.66b / FCF TTM -311.0m)
FCF Yield = -18.78% (FCF TTM -311.0m / Enterprise Value 1.66b)
FCF Margin = -278.8% (FCF TTM -311.0m / Revenue TTM 111.6m)
Net Margin = -279.3% (Net Income TTM -311.6m / Revenue TTM 111.6m)
Gross Margin = 91.60% ((Revenue TTM 111.6m - Cost of Revenue TTM 9.37m) / Revenue TTM)
Gross Margin QoQ = 86.10% (prev none%)
Tobins Q-Ratio = 3.00 (Enterprise Value 1.66b / Total Assets 551.8m)
Interest Expense / Debt = 0.87% (Interest Expense 3.01m / Debt 345.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -195.1m (EBIT -247.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.64 (Total Current Assets 529.8m / Total Current Liabilities 114.2m)
Debt / Equity = 2.99 (Debt 345.4m / totalStockholderEquity, last quarter 115.4m)
Debt / EBITDA = -0.78 (negative EBITDA) (Net Debt 228.6m / EBITDA -294.8m)
Debt / FCF = -0.74 (negative FCF - burning cash) (Net Debt 228.6m / FCF TTM -311.0m)
Total Stockholder Equity = 194.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.74% (Net Income -311.6m / Total Assets 551.8m)
RoE = -160.6% (Net Income TTM -311.6m / Total Stockholder Equity 194.0m)
RoCE = -46.99% (EBIT -247.0m / Capital Employed (Equity 194.0m + L.T.Debt 331.6m))
RoIC = -69.70% (negative operating profit) (NOPAT -195.1m / Invested Capital 279.9m)
WACC = 8.27% (E(1.77b)/V(2.11b) * Re(9.75%) + D(345.4m)/V(2.11b) * Rd(0.87%) * (1-Tc(0.21)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.29%
Fair Price DCF = unknown (Cash Flow -311.0m)
EPS Correlation: -2.77 | EPS CAGR: 22.85% | SUE: 1.61 | # QB: 1
Revenue Correlation: 48.13 | Revenue CAGR: -23.71% | SUE: -0.07 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.54 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.60 | Chg30d=+0.139 | Revisions Net=+1 | Growth EPS=+47.9% | Growth Revenue=+120.2%